Telos Capital Management Inc. Acquires 1,605 Shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

Telos Capital Management Inc. increased its holdings in shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) by 10.0% during the fourth quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 17,627 shares of the pharmaceutical company’s stock after purchasing an additional 1,605 shares during the period. Telos Capital Management Inc.’s holdings in Vertex Pharmaceuticals were worth $7,098,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently modified their holdings of VRTX. Northwest Investment Counselors LLC bought a new position in shares of Vertex Pharmaceuticals during the third quarter valued at approximately $25,000. Highline Wealth Partners LLC bought a new position in shares of Vertex Pharmaceuticals during the third quarter valued at approximately $27,000. Dunhill Financial LLC boosted its stake in shares of Vertex Pharmaceuticals by 70.6% during the third quarter. Dunhill Financial LLC now owns 58 shares of the pharmaceutical company’s stock valued at $27,000 after purchasing an additional 24 shares in the last quarter. Brown Lisle Cummings Inc. bought a new position in shares of Vertex Pharmaceuticals during the fourth quarter valued at approximately $30,000. Finally, Legacy Investment Solutions LLC bought a new position in shares of Vertex Pharmaceuticals during the third quarter valued at approximately $33,000. 90.96% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

VRTX has been the subject of a number of analyst reports. Raymond James reissued a “market perform” rating on shares of Vertex Pharmaceuticals in a research report on Thursday, October 10th. Canaccord Genuity Group increased their target price on shares of Vertex Pharmaceuticals from $361.00 to $408.00 and gave the company a “sell” rating in a research report on Wednesday, November 6th. Morgan Stanley increased their target price on shares of Vertex Pharmaceuticals from $473.00 to $476.00 and gave the company an “equal weight” rating in a research report on Tuesday, November 5th. Wells Fargo & Company cut shares of Vertex Pharmaceuticals from an “overweight” rating to an “equal weight” rating and set a $460.00 target price for the company. in a research report on Thursday, January 30th. Finally, Cantor Fitzgerald reissued an “overweight” rating and set a $480.00 target price on shares of Vertex Pharmaceuticals in a research report on Friday, January 31st. One research analyst has rated the stock with a sell rating, nine have assigned a hold rating, seventeen have given a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $502.58.

Vertex Pharmaceuticals Trading Down 1.5 %

VRTX stock opened at $481.16 on Friday. The company has a debt-to-equity ratio of 0.01, a quick ratio of 2.20 and a current ratio of 2.47. The firm’s fifty day moving average is $435.51 and its 200 day moving average is $462.74. Vertex Pharmaceuticals Incorporated has a one year low of $377.85 and a one year high of $519.88.

Vertex Pharmaceuticals (NASDAQ:VRTX) last released its quarterly earnings results on Monday, November 4th. The pharmaceutical company reported $4.38 EPS for the quarter, beating the consensus estimate of $3.61 by $0.77. The company had revenue of $2.77 billion for the quarter, compared to analyst estimates of $2.69 billion. Vertex Pharmaceuticals had a negative net margin of 4.52% and a negative return on equity of 1.91%. The firm’s revenue was up 11.6% on a year-over-year basis. During the same quarter last year, the business earned $3.67 earnings per share. On average, sell-side analysts forecast that Vertex Pharmaceuticals Incorporated will post -1.93 EPS for the current fiscal year.

Vertex Pharmaceuticals Profile

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.